Physiological and pharmacological implications of AT1 versus AT2 receptors. 1998

O Chung, and H Kühl, and M Stoll, and T Unger
Institute of Pharmacology, University of Kiel, Germany.

Angiotensin II (Ang II) has diverse physiological actions that lead, for instance, to increases in extracellular volume and peripheral vascular resistance and blood pressure, and it has also been implicated in the regulation of cell growth and differentiation. Molecular cloning and pharmacological studies have defined two major classes of Ang II receptors, designated AT1 and AT2. Most effects of Ang II are mediated by AT1 receptors. Much less is known about the physiological role of AT2 receptors. Recent evidence suggests involvement of AT2 receptors in development, cell differentiation, apoptosis, and regeneration in various tissues. AT1 and AT2 receptors have been shown to exert counteracting effects on cellular growth and differentiation, vascular tone, and the release of arginine vasopressin. In each condition, the AT2 receptor appears to down-modulate actions mediated by the AT1 receptor, resulting in decreased cellular proliferation, decreased levels of serum arginine vasopressin levels, or decreased vasoconstrictor responses. In addition, in neuronal cell lines, the AT2 receptor exerts antiproliferative actions and promotes neurite outgrowth, an effect accompanied by significant changes in the expression pattern of growth/differentiation-related genes.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D011945 Receptors, Angiotensin Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells. Angiotensin Receptor,Angiotensin Receptors,Angiotensin II Receptor,Angiotensin III Receptor,Receptor, Angiotensin II,Receptor, Angiotensin III,Receptor, Angiotensin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000803 Angiotensin I A decapeptide that is cleaved from precursor angiotensinogen by RENIN. Angiotensin I has limited biological activity. It is converted to angiotensin II, a potent vasoconstrictor, after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME.
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D057911 Angiotensin Receptor Antagonists Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR. Angiotensin II Receptor Antagonist,Angiotensin II Receptor Blocker,Angiotensin Receptor Antagonist,Angiotensin Receptor Blocker,Angiotensin II Receptor Antagonists,Angiotensin II Receptor Blockers,Angiotensin Receptor Blockers,Antagonist, Angiotensin Receptor,Antagonists, Angiotensin Receptor,Blocker, Angiotensin Receptor,Receptor Antagonist, Angiotensin,Receptor Antagonists, Angiotensin,Receptor Blocker, Angiotensin,Receptor Blockers, Angiotensin

Related Publications

O Chung, and H Kühl, and M Stoll, and T Unger
January 1996, Blood pressure. Supplement,
O Chung, and H Kühl, and M Stoll, and T Unger
January 1999, Journal of the American Society of Nephrology : JASN,
O Chung, and H Kühl, and M Stoll, and T Unger
October 1997, Japanese circulation journal,
O Chung, and H Kühl, and M Stoll, and T Unger
January 1996, Clinical and experimental pharmacology & physiology. Supplement,
O Chung, and H Kühl, and M Stoll, and T Unger
September 1996, Clinical and experimental pharmacology & physiology,
O Chung, and H Kühl, and M Stoll, and T Unger
September 2004, Journal of inflammation (London, England),
O Chung, and H Kühl, and M Stoll, and T Unger
January 1996, Advances in experimental medicine and biology,
O Chung, and H Kühl, and M Stoll, and T Unger
January 2003, Blood pressure,
O Chung, and H Kühl, and M Stoll, and T Unger
December 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
O Chung, and H Kühl, and M Stoll, and T Unger
May 1997, Endocrinology,
Copied contents to your clipboard!